fda warning about compounded semaglutide Overdoses Tied to Hospitalizations Compound versions of GLP-1 drugs

By Route of Administration: Parenteral dominates, Oral growing fastest Parenteral (subcutaneous injection) delivery held the dominant route of administration position in 2025, reflecting that all high-dose, high-efficacy GLP-1 formulations currently approved for obesity management require injection for the delivery of drug quantities sufficient to achieve therapeutic plasma concentrations

Microdose tirzepatide uses a lower-dose version of that dual-pathway strategy

Once GLP-1 was combined with exendin-4, the GLP-1s were present in the bloodstream for much longer

If you dont meet the above criteria, you may still be prescribed semaglutide for off-label use, which refers to use outside of FDA approval